Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,002.31
-0.5%		$932.32
$661.85
▼
$1,072.75
$63.00B0.47263,761 shs209,930 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$33.04
-1.5%		$30.85
$23.62
▼
$35.43
$20.92B0.842.49 million shs2.13 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$135.61
-3.4%		$89.93
$22.28
▼
$176.66
$56.02B1.133.35 million shs8.62 million shs
Natera, Inc. stock logo
NTRA
Natera
$330.31
+1.9%		$295.87
$157.43
▼
$343.18
$46.72B1.541.17 million shs707,199 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-0.47%-5.03%+15.73%+11.50%+30.68%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-1.46%-3.45%+7.03%+30.90%+18.72%
Moderna, Inc. stock logo
MRNA
Moderna
-3.36%-10.08%+126.73%+173.19%+454.19%
Natera, Inc. stock logo
NTRA
Natera
+1.90%+1.58%+3.76%+50.67%+87.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$1,002.31
-0.5%		$932.32
$661.85
▼
$1,072.75
$63.00B0.47263,761 shs209,930 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$33.04
-1.5%		$30.85
$23.62
▼
$35.43
$20.92B0.842.49 million shs2.13 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$135.61
-3.4%		$89.93
$22.28
▼
$176.66
$56.02B1.133.35 million shs8.62 million shs
Natera, Inc. stock logo
NTRA
Natera
$330.31
+1.9%		$295.87
$157.43
▼
$343.18
$46.72B1.541.17 million shs707,199 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-0.47%-5.03%+15.73%+11.50%+30.68%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-1.46%-3.45%+7.03%+30.90%+18.72%
Moderna, Inc. stock logo
MRNA
Moderna
-3.36%-10.08%+126.73%+173.19%+454.19%
Natera, Inc. stock logo
NTRA
Natera
+1.90%+1.58%+3.76%+50.67%+87.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,158.6115.59% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5019.55% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-43.42% Downside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$330.830.16% Upside

Current Analyst Ratings Breakdown

Latest GMAB, ARGX, MRNA, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Natera, Inc. stock logo
NTRA
Natera
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $435.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
argenex SE stock logo
ARGX
argenex
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$1,150.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
9/1/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/31/2026
argenex SE stock logo
ARGX
argenex
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,230.00 ➝ $1,250.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B14.76$21.23 per share47.21$118.34 per share8.47
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.54$1.59 per share20.83$9.10 per share3.63
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B27.85N/AN/A$22.14 per share6.13
Natera, Inc. stock logo
NTRA
Natera
$2.31B20.65N/AN/A$12.38 per share26.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0438.4926.891.0432.19%43.59%36.66%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2726.0220.781.8919.08%14.89%7.73%11/5/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A33,031.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)

Latest GMAB, ARGX, MRNA, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Natera, Inc. stock logo
NTRA
Natera
5.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,119623.78 million614.17 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable

Recent News About These Companies

BlueCrest Capital Management Ltd Purchases New Holdings in Natera, Inc. $NTRA
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bluecrest-capital-management-ltd-purchases-new-holdings-in-natera-inc-ntra-2026-09-10/
Amundi Buys 9,338 Shares of Natera, Inc. $NTRA
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-buys-9338-shares-of-natera-inc-ntra-2026-09-10/
3 reasons investors love Natera (NTRA)
September 9 at 2:43 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/3-reasons-investors-love-natera-ntra/ar-AA2bTSkZ
UBS Group Begins Coverage on Natera (NASDAQ:NTRA)
September 9 at 10:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ubs-group-begins-coverage-on-natera-nasdaq-ntra-2026-09-09/
Billionaire Stanley Druckenmiller’s Largest Holding Is a Healthcare Firm That Has Surged Nearly 10x in Three Years
September 9 at 9:43 AM  |  dailyhodl.comD
C WorldWide Group Holding A S Sells 20,000 Shares of Natera, Inc. $NTRA
September 9 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-c-worldwide-group-holding-a-s-sells-20000-shares-of-natera-inc-ntra-2026-09-09/
Natera (NASDAQ:NTRA) Rating Increased to Strong-Buy at Rothschild & Co Redburn
September 9 at 7:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-natera-nasdaq-ntra-rating-increased-to-strong-buy-at-rothschild-co-redburn-2026-09-09/
HighTower Advisors LLC Increases Stake in Natera, Inc. $NTRA
September 9 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hightower-advisors-llc-increases-stake-in-natera-inc-ntra-2026-09-09/
Natera, Inc. $NTRA Shares Acquired by Hsbc Holdings PLC
September 9 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-acquired-by-hsbc-holdings-plc-2026-09-09/
Natera, Inc. $NTRA Position Increased by Saudi Central Bank
September 8 at 5:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-position-increased-by-saudi-central-bank-2026-09-08/
California State Teachers Retirement System Has $15.29 Billion Holdings in Natera, Inc. $NTRA
September 8 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-has-1529-billion-holdings-in-natera-inc-ntra-2026-09-08/
Natera (NASDAQ:NTRA) Insider Sells $4,955,652.40 in Stock
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31007198
Nykredit A S Purchases Shares of 57,455 Natera, Inc. $NTRA
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-purchases-shares-of-57455-natera-inc-ntra-2026-09-05/
Natera (NASDAQ:NTRA) CEO Sells $545,041.02 in Stock
September 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ntra-insider-buying-and-selling-2026-09-04/
Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 1,698 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-natera-nasdaq-ntra-ceo-sells-1698-shares-of-stock-2026-09-03/
Natera (NASDAQ:NTRA) Insider Sells 3,000 Shares
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-natera-nasdaq-ntra-insider-sells-3000-shares-2026-09-03/
Natera (NASDAQ:NTRA) Insider Sells 15,160 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-natera-nasdaq-ntra-insider-sells-15160-shares-of-stock-2026-09-03/
Natera, Inc. $NTRA Shares Sold by Nwam LLC
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-nwam-llc-2026-09-03/
Natera, Inc. $NTRA Position Trimmed by Braidwell LP
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-position-trimmed-by-braidwell-lp-2026-09-03/
Jupiter Topco LLC Buys Shares of 10,826 Natera, Inc. $NTRA
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-buys-shares-of-10826-natera-inc-ntra-2026-09-03/
Natera, Inc. Announces Clinical Validation Of Signatera For MRD Assessment In Lymphoma
September 2, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
argenex stock logo

argenex NASDAQ:ARGX

$1,002.31 -4.76 (-0.47%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$1,000.00 -2.31 (-0.23%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$33.04 -0.49 (-1.46%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$32.78 -0.27 (-0.80%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$135.61 -4.72 (-3.36%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$137.76 +2.14 (+1.58%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera stock logo

Natera NASDAQ:NTRA

$330.31 +6.17 (+1.90%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$331.16 +0.85 (+0.26%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas